| Literature DB >> 26619937 |
Tatyana Kuznetsova1, Shuang-Yin Wang2, Nagesha A Rao3, Amit Mandoli4, Joost H A Martens5, Nils Rother6, Aafke Aartse7, Laszlo Groh8, Eva M Janssen-Megens9, Guoliang Li10, Yijun Ruan11, Colin Logie12, Hendrik G Stunnenberg13.
Abstract
BACKGROUND: The impact of signal-dependent transcription factors, such as glucocorticoid receptor and nuclear factor kappa-b, on the three-dimensional organization of chromatin remains a topic of discussion. The possible scenarios range from remodeling of higher order chromatin architecture by activated transcription factors to recruitment of activated transcription factors to pre-established long-range interactions.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26619937 PMCID: PMC4665721 DOI: 10.1186/s13059-015-0832-9
Source DB: PubMed Journal: Genome Biol ISSN: 1474-7596 Impact factor: 13.583
Fig. 1Activated glucocorticoid receptor (GR) recruits P300 to epigenomically latent genomic regions. a Color profile depicting the GR and P300 signal at all GR-bound regions with either constitutive or ligand (triamcinolone acetonide [TA]) -induced P300 occupancy. b Example screenshot depicting the TA-induced P300 distal binding site (DBS; dotted box) and constitutive P300 DBS. c Basal (untreated cells) H3K27ac, DNase I hypersensitive site, and H3K4me1 signal at all GR-induced and constitutive P300 DBSs. d Motif occurrence at all GR-bound DBSs presented as a function of TA-dependent P300 recruitment (x-axis). DMSO dimethyl sulfoxide, RE response elements
Fig. 2P300 ChIA-PET interaction profile shows an enhancer-centered interaction pattern in contrast to promoter-centered RNA polymerase II (POLII) interactome. a Proportion of distal binding site (DBS)-promoter, promoter-promoter, and DBS-DBS interactions identified by P300 ChIA-PET in cells treated by vehicle (dimethyl sulfoxide [DMSO]) (upper panel) or triamcinolone acetonide (TA) + tumor necrosis factor alpha (TNFα) (lower panel). b Proportion of DBS-promoter, promoter–promoter, and DBS–DBS interactions identified by POLII ChIA-PET in cells treated with vehicle (upper panel) or TA + TNFα (lower panel). c Venn diagram depicting the extent of overlap between P300 interaction subdomains and POLII interaction subdomains (upper panel). Histogram depicting the percentage of P300 and POLII shared anchors in P300 & POLII interaction subdomains (lower panel). d Example screenshots of P300-rich (left panel), P300 & POLII-rich (middle panel), and POLII-rich (right panel) interaction subdomains depicting the ChIP-seq and ChIA-PET interaction data. e Distribution of glucocorticoid receptor (GR) (left panel) and p65 (right panel) binding sites in P300 rich, P300 & POLII-rich, and POLII-rich interaction subdomains
Fig. 3Glucocorticoid receptor (GR)-dependent and p65 activation-dependent changes in chromatin interactions. a, b Direct comparison of chromatin contacts revealed by P300 ChIA-PET and 4C-seq analyses at the ZBTB16 (a) and KLF6 loci (b). 4C-seq bait loci are marked on each screenshot (blue arrow). Genomic regions that show a marked change in 4C signal upon triamcinolone acetonide (TA) + tumor necrosis factor alpha (TNFα) treatment are marked red below the Δ4C track. c Direct comparison of changes in average ChIP-seq signal (left panel) and 4C signal (right panel) at all the constitutive P300 distal binding sites (DBSs) within the ten 4C-seq genomic view points upon TA + TNFα treatment. d Direct comparison of changes in average ChIP-seq signal (left panel) and 4C signal (right panel) at all the induced P300 DBSs within the ten 4C-seq genomic view points upon TA + TNFα treatment. DMSO dimethyl sulfoxide
Fig. 4Ligand-induced enhancement of chromatin contacts within P300 interaction subdomains. a Bar plot depicting the percentage of induced P300 peaks in the P300 hubs with at least five P300 peaks. b P300 local concentration at all P300 interaction subdomains that are ordered based on average P300 density (x-axis) and ligand-induced change in P300 concentration (y-axis). Sub-domains harboring at least five P300 distal binding sites (DBS) are presented. c Total number of chromatin interactions detected at each interaction subdomain upon vehicle dimethyl sulfoxide (DMSO, blue dots) and triamcinolone acetonide (TA) + tumor necrosis factor alpha (TNFα, red dots) treatment is presented. Sub-domains that show no more than 25 % change in total P300 concentration (reads per kilobase per million mapped reads) that either harbor at least one induced P300 DBS (upper panel) and only constitutive P300 DBS (lower panel) are used. p-values (Mann–Whitney) were generated by comparing interaction ratios (TA + TNFα/DMSO) between the induced and constitutive subdomains that are within each bin (shaded area). d Proportion of DBSs to nearest first gene promoters or DBSs to distal gene promoter interactions identified by P300 and RNA polymerase II (POLII) ChIA-PET analysis. TSS transcription start site. e Co-activation-dependent changes in expression of genes that are directly looped to P300 DBSs. P300 DBSs were initially ordered according to agonist-induced P300 recruitment (low to high) and subsequently divided into 10 equal bins. The average transcriptional change of genes in each bin is presented. Expression of genes that are in bins harboring significantly repressed (gray), induced (red), and constitutive (blue) P300 DBSs upon co-stimulation. f Co-activation-induced changes in expression of genes that are within interaction subdomains harboring either induced or only constitutive P300 DBSs